Exo Biologics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $8.27M

  • Investors
  • 4

Exo Biologics General Information

Description

Developer of novel therapeutic candidates based on exosomes designed to assist in treating dysplasia and Crohn's disease. The company's large-scale, cost-effective, and consistent candidates provide intracellular communication between cells, transfer of proteins, lipids, and genetic material, and signaling to the recipient cell via cell surface or endosomal receptors, enabling patients with unmet medical needs to get affordable and accessible therapy.

Contact Information

Website
www.exobio.be
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Boulevard de Patience et Beaujonc, 3/2
  • 4000 Liege
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Boulevard de Patience et Beaujonc, 3/2
  • 4000 Liege
  • Belgium

Exo Biologics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exo Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 24-Apr-2024 $8.27M Completed Clinical Trials - Phase 1
3. Early Stage VC 12-Oct-2023 Completed Clinical Trials - Phase 1
2. Early Stage VC 02-May-2021 $5.98M $5.98M Completed Clinical Trials - Phase 1
1. Grant 02-May-2021 $4.43M Completed Clinical Trials - Phase 1
To view Exo Biologics’s complete valuation and funding history, request access »

Exo Biologics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
C Shares
A Shares
C Shares
B Shares
A Shares
C Shares
B Shares 8,467 $380.76 $380.76 1x $380.76 8.26%
A Shares 16,214 $331.39 $331.39 1x $331.39 15.81%
To view Exo Biologics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Exo Biologics Patents

  • 26

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Exo Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026209839-A1 Isolated extracellular vesicles and their use in the prevention or treatment of hair loss disorders Pending 01-Apr-2025
WO-2026139617-A1 Isolated extracellular vesicles and their use Pending 24-Dec-2024
WO-2026082921-A1 Extracellular vesicles for the treatment of ocular surface disease Pending 18-Oct-2024
JP-7904816-B2 Extracellular vesicles (evs) derived from mesenchymal stromal cells and a method for obtaining the evs. Active 09-Jul-2020
AU-2021303493-A1 Extracellular vesicles (evs) derived from mesenchymal stromal cells and method for obtaining said evs Pending 09-Jul-2020 C12N5/0665
To view Exo Biologics’s complete patent history, request access »

Exo Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exo Biologics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Founders Accelerator/Incubator Minority
Noshaq Venture Capital Minority
Scorpiaux PE/Buyout Minority
Walloon Region Government Minority
To view Exo Biologics’s complete investors history, request access »

Ready to get started?

Request a free trial

Exo Biologics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
ExoXpert Liege, Belgium 2023

Exo Biologics FAQs

  • When was Exo Biologics founded?

    Exo Biologics was founded in 2019.

  • Where is Exo Biologics headquartered?

    Exo Biologics is headquartered in Liege, Belgium.

  • What is the size of Exo Biologics?

    Exo Biologics has 18 total employees.

  • What industry is Exo Biologics in?

    Exo Biologics’s primary industry is Drug Discovery.

  • Is Exo Biologics a private or public company?

    Exo Biologics is a Private company.

  • What is the current valuation of Exo Biologics?

    The current valuation of Exo Biologics is .

  • What is Exo Biologics’s current revenue?

    The current revenue for Exo Biologics is .

  • How much funding has Exo Biologics raised over time?

    Exo Biologics has raised $17.4M.

  • Who are Exo Biologics’s investors?

    Founders, Noshaq, Scorpiaux, and Walloon Region have invested in Exo Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process